Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2

Valproate (VPA) has been used in the treatment of bipolar disorder since the 1990s. However, the therapeutic targets of VPA have remained elusive. Here we employ a preclinical model to identify the therapeutic targets of VPA. We find compounds that inhibit histone deacetylase proteins (HDACs) are ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Logan, Ryan W., Ozburn, Angela R., Arey, Rachel N., Ketchesin, Kyle D., Winquist, Alicia, Crain, Andrew, Tobe, Brian T. D., Becker-Krail, Darius, Jarpe, Matthew B., Xue, Xiangning, Zong, Wei, Huo, Zhiguang, Parekh, Puja K., Zhu, Xiyu, Fitzgerald, Ethan, Zhang, Hui, Oliver-Smith, Jeffrey, DePoy, Lauren M., Hildebrand, Mariah A., Snyder, Evan Y., Tseng, George C., McClung, Colleen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141541/
https://www.ncbi.nlm.nih.gov/pubmed/33235333
http://dx.doi.org/10.1038/s41380-020-00958-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141541/
https://www.ncbi.nlm.nih.gov/pubmed/33235333
http://dx.doi.org/10.1038/s41380-020-00958-2

Ejemplares similares